Locomotion disorders in companion animals are of two main kinds: arthritis (in dogs, in particular) and lameness in horses.


Ceva Santé Animale has developed a set of specific solutions using renowned molecules to treat arthritis and its consequences.

  • CARPRODYL (carprofen)

Carprofen is a non-narcotic, non-steroidal anti-inflammatory drug with characteristic analgesic and antipyretic properties that are almost equivalent to those shown by indomethacin in studies on animal models. Carprofen blocks acute and chronic inflammatory reactions and is used in adjunct treatments of joint inflammations.

  • MELOXIDYL® (meloxicam)

Meloxicam is used to treat inflammation and pain. It is used in short-term treatment of inflammatory conditions and arthritis, and in long-term treatment of chronic joint inflammations (polyarthritis, ankylosing spondylitis).

  • FLEXIVET Start (chondroitin - glucosamine) - FLEXIVET Go (glucosamine)

FLEXIVET Start combines two chondro-protectors, chondroitin and glucosamine. Marine chondroitin guarantees a majority of active isomers and offers risk-free use. One month’s administration of FLEXIVET Start limits deterioration of the cartilage and encourages macro-molecular synthesis of joint cartilage in the animals.
Administration of FLEXIVET Start (initial treatment) for one month should be followed by administration of FLEXIVET Go (maintenance - glucosamine alone) for at least two months.


Lameness is one of the major pathologies in horses and one of the main reasons for visits to equine vets.
All categories of horses are concerned, from those used for leisure activities through to racehorses...
Locomotion pathologies often cause intense pain leading to clear-cut lameness.

However, depending on the location of lesions and intensity of the pain, such disorders may have less marked clinical manifestations, generating symptoms that are highly variable in their intensity.
Discomfort, manifested by an irregular or asymmetrical gait, may handicap racehorses or competition horses: this type of atypical lameness can lead to a drop in the performance of these athletes.
The origins of lameness may vary, but treatment often boils down to symptomatic anti-inflammatory injections.

As early as 2001, Ceva Santé Animale produced a molecule to treat the cause of bone-related lameness: injectable tiludronate (TILDREN®)

Irrespective of the age of the horse, the bone tissue of the skeleton is constantly being renewed. These continual changes to bone tissue are a normal process: they allow the skeleton to adapt to specific mechanical constraints, for example those related to the horse’s sport.

Sometimes bone renewal goes into overdrive. Because of the intense work by the horse or excessive mechanical stress on a bone or a joint, bone areas that are "working too hard" will be rearranged even more extensively. These excessive rearrangements of the bone tissue are to be found in a large number of locomotion disorders that horses suffer from, in particular in most degenerative bone and joint disorders. Additionally, it is precisely this bone rearrangement which causes the pain responsible for the lameness.
A large proportion of locomotion disorders in horses are thus caused by variations in bone structure, generally visible on X-rays.

Tiludronate demonstrates positive effects on mineralisation and increases bone density. TILDREN® acts on the ongoing bone remodelling processes and is used to treat bone diseases such as spavin or navicular syndrome that generate very serious lameness in horses for competition and leisure.

For more information on TILDREN®

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top